【国投证券 | 医药】凯莱英三季度报点评:2025Q4交付订单规模有望环比提升,收入有望稳健增长

国投证券医药研究
Nov 03

事件:公司发布了2025年第三季度报告,2025年前三季度公司实现营收46.30亿元,同比增长11.82%;实现归母净利润8.00亿元,同比增长12.66%。2025Q4交付订单规模有望环比提升,全年收入稳增长可期:收入端,2025Q1-Q3公司实现营收46.30亿元,同比增长11.82%。其中,2025Q1-Q3小分子业务收入与去年同期相比基本持平,新兴业务收入同比增长71.87%。从下半年待...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10